Astromech has acquired Colossal spinout Form Bio in an all-stock deal valued at $230 million, folding gene-medicine design tools into its evolutionary AI platform.
Key Takeaways
- Astromech paid $230M in stock for Form Bio, announced November 17, 2026.
- Form Bio co-founder Andrew Busey becomes Astromech's Chief AI Officer and Head of Technology.
- Astromech was valued at $3.8B in August and has raised $60M in total.
Lead
Astromech, the evolutionary-prediction AI startup co-founded by Ben Lamm and George Church, announced on November 17, 2026 that it had acquired Form Bio in an all-stock transaction valued at $230 million. The deal moves Form Bio's intellectual property, selected contracts and assets, and team into Astromech. Both companies came out of Colossal Biosciences, so this is a sister-company merger rather than a purchase between strangers.
The structure matters. No cash changed hands, and the price is denominated in shares of a company that last priced itself at $3.8 billion in August. Form Bio's own valuation at the time of the deal was not disclosed.
What Did Astromech Actually Buy?
Astromech bought a software and talent stack for designing genetic medicines, not a drug pipeline. Form Bio was founded in September 2022 by Andrew Busey, Ben Lamm and Kent Wakeford, and builds models and tools that help researchers design gene therapies and make them easier to manufacture. Its customers have included Eli Lilly, Stanford University, Taysha Gene Therapies, Coave Therapeutics, Solid Biosciences and Cure Rare Disease.
The Form Bio AI, engineering and product teams move to Astromech, which will have about 65 employees after the deal. Busey takes the chief AI officer role and will lead the combined AI and technology work.
Why Did Astromech Pay $230M in Stock?
Astromech paid in stock because it has an expensive currency and, so far, no commercial product with revenue. Astromech describes itself as a prediction company. Its models use genetic and evolutionary data to forecast how genomes and populations change, with uses such as anticipating drug resistance in pathogens or identifying species at risk. Form Bio supplies the applied end of that pipeline: tools that turn biological design decisions into therapies.
This is a strategic purchase, not an acquihire. Form Bio brings existing customers, software and a team that has shipped product, which Astromech's research-stage models lacked. Busey said the deal gives the company a chance to build on its progress by "bringing evolutionary insights into the design decisions we help researchers make."
The price also deserves scrutiny. Form Bio raised a $30 million Series A led by JAZZ Venture Partners at its 2022 launch, and has raised over $40 million in venture financing in total by one count (PitchBook lists $64 million). A $230 million exit is a multiple of that capital, but the payout arrives as paper in a private company, not as cash.
How Does the Deal Fit Astromech's Funding Path?
The acquisition follows a fast fundraising sequence. Astromech emerged from stealth in March 2026 and closed a $20 million round in August that lifted its total raised to $60 million at a $3.8 billion valuation. Investors in the August round included biotech investor Bob Nelsen, Peak 6, NeoGenesis Capital, Builders VC and CAZ Investments. The company plans to raise again next year.
That valuation sits at roughly 63 times total capital raised, a ratio that reflects the Colossal brand and Church's reputation more than revenue. Using shares to buy a customer-facing business gives investors in the next round something more concrete to evaluate: a product, a client list and a larger team.
What Does It Mean for Colossal's Spinout Strategy?
The deal shows Colossal consolidating its offshoots instead of letting them compete for the same talent and capital. Colossal, founded in 2021, is Texas's first decacorn, with a valuation above $10 billion. Its spinouts include Form Bio, Astromech and Breaking, which works on plastic degradation. Combining two companies that share a founder in Lamm removes duplication and simplifies the cap table story ahead of Astromech's next raise.
The related-party nature of the transaction also invites questions. Lamm co-founded both companies, and the price was set between entities with overlapping founders and backers. The terms around any independent valuation or approval were not disclosed.
What Comes Next for Astromech?
Integration is the near-term test. Astromech must show that evolutionary models can improve gene-medicine design in ways customers will pay for, and that Form Bio's existing contracts survive the transition. Form Bio's customers sit in a gene therapy sector where funding has been tight, which limits how fast revenue can grow.
Two scenarios are plausible. If the combined product lands pilot deals with pharma groups, the 2027 round could price above $3.8 billion. If it does not, the stock used here becomes a higher-priced marker that investors may resist repeating.
Outlook
Astromech has turned a $230 million paper transaction into a larger team, a customer base and a product line that connects prediction to therapy design. The real measure will be the 2027 fundraising, where investors will judge whether the Form Bio assets support a $3.8 billion valuation or push it higher. Until then, the deal is a bet by Colossal's founders that evolutionary AI belongs inside the drug design workflow.



